Towards precision medicine in non-alcoholic fatty liver disease.

Francque SM. Rev Endocr Metab Disord. 2023;24(5):885-899.

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.

Harrison SA, Bedossa P, Guy CD, et al. N Engl J Med. 2024;390(6):497-509.

Tirzepatide once weekly for the treatment of obesity.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216.

Karim G, Bansal MB. Resmetirom: an orally administered, small molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol. 2023;19(1):60-70.

Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis.

Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Gastroenterology. 2020;159(4):1290-1301.e1295.

Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.

Loomba R, Abdelmalek MF, Armstrong MJ, et al. Lancet Gastroenterol Hepatol. 2023;8(6):511-522.

Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis.

Loomba R, Hartman ML, Lawitz EJ, et al. N Engl J Med. 2024;391(4):299-310.

A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.

Newsome PN, Buchholtz K, Cusi K, et al. N Engl J Med. 2021;384(12):1113-1124.

Expert panel recommendations: practical clinical applications for initiating and monitoring resmetirom in patients with MASH/NASH and moderate to noncirrhotic advanced fibrosis.

Noureddin M, Charlton MR, Harrison SA, et al. Clin Gastroenterol Hepatol. 2024:S1542-3565(24)00667-0.

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

Noureddin N, Copur-Dahi N, Loomba R. Aliment Pharmacol Ther. 2024;59(suppl 1):S41-S51.

A randomized, controlled trial of 3.0 mg of liraglutide in weight management.

Pi-Sunyer X, Astrup A, Fujioka K, et al. N Engl J Med. 2015;373(1):11-22.

A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Rinella ME, Lazarus JV, Ratziu V, et al. Hepatology. 2023;78(6):1966-1986.

Once-weekly semaglutide in adults with overweight or obesity.

Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002.

The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes.

Younossi ZM, Golabi P, Price JK, et al. Clin Gastroenterol Hepatol. 2024;22(10):1999-2010.e1998.